nach oben

Clinical and Translational Oncology

Erschienen in:

02.11.2015 | Research Article

ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker

verfasst von: M.- J. Zhang, C.- Z. Zhang, W.- J. Du, X.- Z. Yang, Z.- P. Chen

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

ATPase family, AAA domain containing 2 (ATAD2) has been found overexpressed in various cancer types and correlated with malignant status and poor prognosis. However, little is known about the clinical significance of ATAD2 in gastric cancer patients. The aim of this study was to explore the clinical and prognostic significance of ATAD2 in gastric cancer.

Methods

The mRNA and protein levels expression of ATAD2 were detected in clinical tissue samples by qRT-PCR and immunohistochemistry, respectively. We examined the ATAD2 protein expression by immunohistochemistry. Furthermore, we analyzed the association between ATAD2 expression and clinicopathological features including prognosis in 166 gastric cancer samples.

Results

In our results, ATAD2 mRNA and protein were highly expressed in gastric cancer samples. ATAD2 overexpression was correlated with advanced clinical stage, tumor depth, lymph node metastasis, and distant metastasis. According to the survival analysis, ATAD2 protein overexpression was a poor independent prognostic factor for gastric cancer patients.

Conclusions

In summary, ATAD2 could serve as a prognostic biomarker for gastric cancer patients.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.CrossRefPubMed

Ye YW, Dong RZ, Zhou Y, Du CY, Wang CM, Fu H, et al. Prognostic analysis of familial gastric cancer in Chinese population. J Surg Oncol. 2011;104(1):76–82. doi:10.1002/jso.21896.CrossRefPubMed

Wang CS, Hsieh CC, Chao TC, Jan YY, Jeng LB, Hwang TL, et al. Resectable gastric cancer: operative mortality and survival analysis. Chang Gung Med J. 2002;25(4):216–27.PubMed

Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. The incidences and mortalities of major cancers in China, 2009. Chin J Cancer. 2013;32(3):106–12. doi:10.5732/cjc.013.10018.CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.CrossRefPubMed

Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. WJG. 2014;20(38):13842–62. doi:10.3748/wjg.v20.i38.13842.CrossRefPubMedPubMedCentral

Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW. ANCCA, an estrogen-regulated AAA + ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA. 2007;104(46):18067–72. doi:10.1073/pnas.0705814104.CrossRefPubMedPubMedCentral

Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69(21):8491–8. doi:10.1158/0008-5472.CAN-09-2131.CrossRefPubMed

Leachman NT, Brellier F, Ferralli J, Chiquet-Ehrismann R, Tucker RP. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev Growth Differ. 2010;52(9):747–55. doi:10.1111/j.1440-169X.2010.01211.x.CrossRefPubMed

10.

Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou L, et al. Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer. Oncol Rep. 2015;33(5):2337–44. doi:10.3892/or.2015.3867.PubMed

11.

Wu G, Liu H, He H, Wang Y, Lu X, Yu Y, et al. miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis. BMC Cancer. 2014;14:107. doi:10.1186/1471-2407-14-107.CrossRefPubMedPubMedCentral

12.

Boussouar F, Jamshidikia M, Morozumi Y, Rousseaux S, Khochbin S. Malignant genome reprogramming by ATAD2. Biochim Biophys Acta. 2013;1829(10):1010–4. doi:10.1016/j.bbagrm.2013.06.003.CrossRefPubMed

13.

Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, et al. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One. 2014;9(1):e85448. doi:10.1371/journal.pone.0085448.CrossRefPubMedPubMedCentral

14.

Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010;70(22):9402–12. doi:10.1158/0008-5472.CAN-10-1199.CrossRefPubMedPubMedCentral

15.

Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010;29(37):5171–81. doi:10.1038/onc.2010.259.CrossRefPubMed

16.

Hsia EY, Kalashnikova EV, Revenko AS, Zou JX, Borowsky AD, Chen HW. Deregulated E2F and the AAA + coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. MCR. 2010;8(2):183–93. doi:10.1158/1541-7786.MCR-09-0095.CrossRefPubMed

17.

Wu G, Lu X, Wang Y, He H, Meng X, Xia S, et al. Epigenetic high regulation of ATAD2 regulates the Hh pathway in human hepatocellular carcinoma. Int J Oncol. 2014;45(1):351–61. doi:10.3892/ijo.2014.2416.PubMed

18.

Hwang HW, Ha SY, Bang H, Park CK. ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection. Cancer Res Treatment Off J Korean Cancer Assoc. 2015;. doi:10.4143/crt.2014.177.

19.

Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, et al. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma. Ann Surg Oncol. 2013;20(Suppl 3):S577–82. doi:10.1245/s10434-013-3027-1.CrossRefPubMed

20.

Wan WN, Zhang YX, Wang XM, Liu YJ, Zhang YQ, Que YH, et al. ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. APJCP. 2014;15(6):2777–83.PubMed

21.

Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, et al. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS One. 2011;6(12):e28503. doi:10.1371/journal.pone.0028503.CrossRefPubMedPubMedCentral

22.

Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, et al. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS ONE. 2013;8(2):e54873. doi:10.1371/journal.pone.0054873.CrossRefPubMedPubMedCentral

23.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. doi:10.1038/35000501.CrossRefPubMed

24.

Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 2009;69(8):3339–46. doi:10.1158/0008-5472.CAN-08-3440.CrossRefPubMed

25.

Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Modern Pathol Off J United States and Canadian Acad Pathol. 2007;20(10):1085–94. doi:10.1038/modpathol.3800937.CrossRef

Titel: ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker
verfasst von: M.- J. Zhang
C.- Z. Zhang
W.- J. Du
X.- Z. Yang
Z.- P. Chen
Publikationsdatum: 02.11.2015
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 8/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1430-8

Springer Medizin

ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker

Abstract

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status

Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients

CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review

Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance

Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer

Pin1 promotes prostate cancer cell proliferation and migration through activation of Wnt/β-catenin signaling

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie